Kodiak Sciences is a biopharmaceutical company researching, developing and commercializing therapeutics for retinal diseases.

Kodiak Sciences

Kodiak Sciences | 9,017 followers on LinkedIn. We are a clinical stage biopharma company bringing new science to prevent and treat high prevalence retinal diseases. | Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak&#39;s discovery engine.

CEO at Xencor

Bassil Dahiyat

Jean Drouin

Gayathrie Janakiraman

Kim Williams

We look forward to participating in a presentation and panel at #InnovateRetina2024 today. See below for details and we look forward to seeing you there! Slides of the presentation will be made available at the beginning of the presentation here: https://lnkd.in/g-w8vFD4

Join us at 10:30am ET today for our Investor R&D Day! The event can be accessed virtually at: https://lnkd.in/gS2_MUKz

We look forward to hosting our Investor R&D Day on Monday, September 23 at 10:30am ET! “We look forward to addressing the most common questions we’ve received from investors about Kodiak today and sharing how we believe our learnings, our course corrections, and our rapid execution will help us move forward,” said Dr. Victor Perlroth, M.D., Chief Executive Officer. Register here for the webcast: https://lnkd.in/gmCRNV28 For more details see our press release: https://lnkd.in/gjfKXc63

Join us tomorrow at 8am ET at the Goldman Sachs 45th Annual Global Healthcare conference. We look forward to providing an update on our tarcocimab tedromer, KSI-501 and KSI-101 clinical programs. A live webcast of the presentation will be available here: https://lnkd.in/evfm2VPr

On June 8, we look forward to presenting important updates on our late-phase clinical program in retina at this year’s Clinical Trials at the Summit meeting. To all those attending, we hope to see you there!

Today is #ClinicalTrialsDay and in honor of all the investigators and participants in our clinical trials and in others, we want to say thank you! We admire and recognize all that you have done to advance vision care around the world. Learn more about CTD2024 by the Association of Clinical Research Professionals (ACRP) here: https://lnkd.in/e9r9k5Wu

We continue to progress our late- and early-phase retina pipeline programs. Learn more in our latest press release: https://lnkd.in/emWeNWr3

We recently reported fourth quarter and full year 2023 financial results and highlighted important updates about our three clinical programs. Read the full press release here: https://lnkd.in/gm7gZmgQ

We look forward to kicking off the new year by sharing an update on Kodiak’s clinical pipeline in retina at the 42nd Annual J.P. Morgan Healthcare Conference. Tune in tomorrow at 10:30 am ET. A live webcast of the presentation will be available here: https://lnkd.in/g3MyHiVB

We look forward to speaking today at the 6th annual Evercore ISI HealthCONx conference! Tune into the live webcast at 3:25pm EST to learn more about Kodiak’s latest developments: https://lnkd.in/g-w8vFD4

IPhone / Mobile Compatible

Content Delivery Network

Google Maps

WordPress

Font Awesome

LetsEncrypt

US Privacy User Signal Mechanism

reCAPTCHA

Apache

Person Schema

Baden-Wurttemberg Advertising Companies

European Union (EU) Social Media Companies

Baden-Wurttemberg Companies With Fewer Than 50 Employees (Top 10K)

Baden-Wurttemberg Companies With Fewer Than 100 Employees (Top 10K)

Kodiak is an advertising studio that offers creative corporate design & campaigns, newsletter marketing, social media, & website creation.

Advertising, Business and Retail Services

Isny Im Allgäu

Baden-Wurttemberg

Germany

Europe

Kodiak

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 14, 2024 11:14 AM	62685a2a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 14, 2024 11:14 AM	96b7a8ef
crunchbase trigger	general	Nov 14, 2024 11:14 AM	7dcdb270
crunchbase profile	general	Nov 15, 2024 2:36 AM	ac8a141d
li profile	general	Nov 14, 2024 11:14 AM	22b46090
translate crunchbase fundingrounds	general	Nov 15, 2024 3:28 AM	b9382255
peers	general	Nov 14, 2024 11:14 AM	72b0efc3
news basic	general	Nov 14, 2024 11:14 AM	2acab7d0
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:KODIAK

Kodiak Sciences

Last Close

5.90

22/11 21:00

Market Cap

132.39M

Beta: -

Volume Today

251.42K

Avg: -